




## Supplementary Material


Figure S1.  $^1\text{H-NMR}$  spectrum for Sclerotigrin A (1) at 500 MHz in  $\text{DMSO-}d_6$ .




**Figure S2.** DQF-COSY spectrum for Sclerotinigrin A (1) in DMSO- $d_6$ .



**Figure S3.** <sup>ed</sup>HSQC spectrum for Sclerotinigrin A (1) in DMSO-*d*<sub>6</sub>

**Figure S4.** HMBC spectrum for Sclerotinigrin A (1) in DMSO- $d_6$ .

**Figure S5.** NOESY spectrum for Sclerotinigrin A (1) in DMSO- $d_6$ 

**Figure S6.**  $^1\text{H}$ -NMR spectrum for Sclerotinigrin B (2) at 500 MHz in  $\text{DMSO-}d_6$ .







Figure S7. DQF-COSY spectrum for sclerotinigrin B (2) in DMSO- $d_6$ .



**Figure S8.** <sup>ed</sup>HSQC spectrum for Sclerotionigrin B (2) in DMSO-*d*<sub>6</sub>.



**Figure S9.** HMBC spectrum for Sclerotinigrin B (2) in DMSO- $d_6$ .



**Figure S10.** NOESY spectrum for Sclerotinigrin B (2) in DMSO- $d_6$ .**Figure S11.** NMR data for proxiphomin (3).


Table S1. NMR data for proxiphomin (3).


No.	$\delta_{\text{H}}$ (integral, mult., J [Hz]) <sup>†</sup>	<sup>13</sup> C-chemical shift [ppm] <sup>†</sup>	HMBC correlations	NOESY connectivities
1	-	173.6	-	-
2	7.94 (1H, s)	-	3, 4, 9	3
3	3.25 (1H, m)	53.0	-	2, 10, 10', 11, 12, 26, 30
4	2.80 (1H, dd, 5.8, 2.6)	47.2	1, 3, 5, 6, 9, 10, 23	5, 10, 10', 11, 26, 30
5	2.20 (1H, m)	33.7	1	4, 8, 11
6	-	139.1	-	-
7	5.27 (1H, m)	125.8	-	8, 12, 13
8	2.63 (1H, m)	47.0	1	7, 5, 13, 14, 22
9	-	65.7	-	-
10	2.40 (1H, dd, 13.2, 7.3)	43.1	1, 3, 4, 25, 26, 30	3, 4, 10', 26, 30
10'	2.60 (1H, dd, 13.2, 4.9)	43.1	1, 3, 4, 25, 26, 30	3, 4, 10, 26, 30
11	0.77 (3H, d, 7.2)	12.6	4, 5, 6	3, 4, 5
12	1.66 (3H, s)	19.3	5, 7	3, 7, 13
13	6.18 (1H, ddd, 15.2, 9.8, 1.7)	129.3	15	7, 8, 12, 14, 22
14	5.11 (1H, ddd, 14.6, 10.3, 3.2)	131.6	8	8, 13, 15'
15	1.67 (1H, m)	39.7	16	15'
15'	1.99 (1H, m)	39.7	16	14, 15, 16, 17 24
16	1.38 (1H, m)	31.9	-	15'
17	1.23 (2H, m)	28.5	-	15', 18
18	1.13 (2H, m)	23.1	-	17
19	1.41 (1H, m)	25.2	-	19'
19'	1.56 (1H, m)	25.2	-	19
20	2.02 (1H, m)	31.1	-	20', 21, 22
20'	2.28 (1H, m)	31.1	-	20
21	6.54 (1H, ddd, 15.4, 10.2, 5.3)	145.7	20, 23	20
22	6.86 (1H, d, 15.5)	127.3	20, 23	8, 13, 20
23	-	196.9	-	-
24	0.85 (3H, d, 6.7)	20.8	15, 16	15'
25	-	136.7	-	-
26‡	7.10 (1H, d, 7.5)	129.5	10, 28, 30	3, 4, 10, 10'
27‡	7.25 (1H, dd, 7.4, 1.0)	127.9	25, 29	
28	7.16 (1H, d, 7.5)	126.0	26, 30	
29‡	7.25 (1H, dd, 7.4, 1.0)	127.9	25, 27	
30‡	7.10 (1H, d, 7.5)	129.5	10, 26, 28	3, 4, 10, 10'

<sup>†</sup> <sup>1</sup>H-NMR data were obtained at 500 MHz in DMSO-*d*<sub>6</sub> and <sup>13</sup>C data were obtained at 125 MHz in DMSO-*d*<sub>6</sub>.

‡It was not possible to distinguish between 26 and 30 as well as 27 and 29.

**Figure S12.**  $^1\text{H}$ -NMR spectrum for proxiphomin (3) at 500 MHz in  $\text{DMSO-}d_6$ .



**Figure S13.** DQF-COSY spectrum for proxiphomin (3) in DMSO-*d*<sub>6</sub>.




**Figure S14.**  $^2\text{D}$ HSQC spectrum for proxiphomin (3) in  $\text{DMSO-}d_6$ .

Figure S15. HMBC spectrum for proxiphomin (3) in DMSO- $d_6$ 

**Figure S16.** NOESY spectrum for proxiphomin (3) in DMSO- $d_6$ .




**Table S2.** Patient data, including age, clinical stage, IGHV mutational status and fluorescence in situ hybridization (FISH) results.

Number	Age	Binet	IGHV	FISH
1	55	A	unmutated	13q-
2	64	A	mutated	13q-
3	48	A	mutated	13q-, Tris 18
4	53	A	mutated	13q-

Mean values  $\pm$  SEM of four CLL samples and three healthy donor samples are depicted.

**Figure S17.** Effects of 1–3 on CLL cell viability. CLL cells were treated for 24 h with increasing concentrations of 1–3 and cell viability was analyzed by CellTiter-Glo® assay. Relative cell viability is compared to DMSO control (0.1%).



**Figure S18.** Effects of 1–3 on healthy B-cells cell viability. Healthy B-cells were treated for 24 h with increasing concentrations of 1–3 and cell viability was analyzed by CellTiter-Glo® assay. Relative cell viability is compared to DMSO control (0.1%).

